On May 15, 2020 TG Therapeutics, Inc. (NASDAQ: TGTX), reported that preclinical data for TG-1701, the Company’s highly selective, BTK inhibitor, has been selected for presentation at the upcoming 2020 American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting, to be held virtually (Press release, TG Therapeutics, MAY 15, 2020, View Source [SID1234558114])
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation details are as follows:
Title: TG-1701, a novel irreversible Bruton’s kinase (BTK) inhibitor, does not inhibit anti-CD20-driven ADCC and ADCP in vitro, and cooperates with the glycoengineered anti-CD20 mAb, ublituximab, in in vivo mantle cell lymphoma models
Abstract Number: 2939
Available on Demand: Monday, June 22, 2020 at 9:00 AM ET
Session Title: Combination Immunotherapies 2
Presenting Author: Gaël Roué, PhD, Lymphoma Translational Group leader, Josep Carreras Leukaemia Research Institute (IJC)
A copy of the above referenced abstract can be viewed online through the AACR (Free AACR Whitepaper) meeting website at www.aacr.org. Following the presentation, the data presented will be available on the Publications page of the Company’s website at www.tgtherapeutics.com/publications.cfm.